Lectures 9 & 10: GI Secretions I & II
HoyaDocs — GI Block | USMLE Step 1 Preparation
Lectures 9 & 10 — Overview
GI Secretions I & II · HoyaDocs GI Block
Page Summaries
Ghrelin · PYY · GLP-1 · Leptin · Salivary composition · Autonomic control · Flow rate
Practice Qs: Q1–Q3
Esoph mucous glands · Cardiac glands · Parietal · Chief · ECL · G/D cells · HCl mechanism · Alkaline tide
Practice Qs: Q4–Q6
Neural control · 3 phases · H. pylori · PPIs · H2 blockers · Vagotomy · Achlorhydria
Practice Qs: Q7–Q9
Acinar cells · Zymogen activation · Enterokinase · CFTR · Brunner's · Paneth cells
Practice Qs: Q10–Q12
Colonic mucus · HCO3⁻/Cl⁻ exchange · K+ secretion · Gastrin · Secretin · CCK · GIP · Motilin · GLP-1
Practice Qs: Q13–Q15
Official Learning Objectives Map
LO 1 — Thirst, Hunger, Satiety & Salivary Secretions
Official LOs 1–4 · HoyaDocs GI Block
- LO 1: PREDICT the effect of loss of sympathetic or parasympathetic nerve input to the salivary glands
- LO 2: DESCRIBE the functions of saliva; LIST systemic factors that reduce salivary flow; IDENTIFY the hormones found in saliva
- LO 3: DESCRIBE the basic mechanisms and hormones regulating satiety and hunger
- LO 4: PREDICT the effects of a marked reduction in salivary flow
- Note: Thirst regulation is covered as supporting background material from the lecture handout.
▼ Thirst & Volume Regulation
⭐ Thirst is regulated by both osmolarity and blood volume, with hypothalamic osmoreceptors as the primary sensor.
💧 Osmotic Thirst
- Stimulus: ↑ plasma osmolarity (even +1–2%) → shrinkage of hypothalamic osmoreceptors
- Location: Anterior hypothalamus (organum vasculosum of lamina terminalis, OVLT)
- Response: Thirst sensation + ADH (vasopressin) release from posterior pituitary → water retention
- Threshold: Osmolarity >290 mOsm/kg triggers thirst; ADH release begins ~280 mOsm/kg
🧠 Hypovolemic Thirst
- Stimulus: ↓ blood volume (≥10% decrease) → activates low-pressure atrial receptors and arterial baroreceptors
- Pathway: ↓ renal perfusion → ↑ renin → ↑ angiotensin II → acts on subfornical organ (SFO) → thirst + ↑ ADH + ↑ aldosterone
- Key mediator: Angiotensin II is the most potent dipsogen (thirst stimulus)
- Osmolarity > volume in sensitivity: a small ↑ osmolarity triggers thirst more reliably than modest volume depletion
- ADH threshold (280 mOsm) is lower than thirst threshold (290 mOsm) — body conserves water before you feel thirsty
- Angiotensin II acts on the SFO (circumventricular organ — outside BBB) to stimulate thirst
▼ Hunger & Satiety Hormones
⭐ The hypothalamic arcuate nucleus integrates hunger and satiety signals via NPY/AgRP (hunger) and POMC/CART (satiety) neurons.
🍕 Ghrelin — "The Hunger Hormone"
- Source: Gastric oxyntic glands (X/A-like cells) — primarily fundus of stomach
- When released: Fasting state; levels peak just before meals
- Receptor: GHS-R1a (growth hormone secretagogue receptor)
- Mechanism: Acts on arcuate nucleus → stimulates NPY (neuropeptide Y) and AgRP neurons → ↑ appetite, ↑ food intake, ↑ fat storage
- Additional effects: Stimulates GH release from anterior pituitary; promotes gastric emptying; prokinetic
- After eating: Ghrelin falls rapidly post-meal
Ghrelin = GRowing hungry — rises before you eat, falls after. "Ghre-lin = Grow-lin" because it also stimulates GH release.
🧦 Peptide YY (PYY) — Satiety from the Gut
- Source: L-cells of distal ileum and colon
- When released: After eating; stimulated by fat and protein entering the distal gut
- Mechanism: Acts on arcuate nucleus → inhibits NPY/AgRP neurons → ↓ appetite, ↓ food intake
- Also known as: "Ileal brake" — slows gastric emptying and intestinal transit
🧮 GLP-1 (Glucagon-Like Peptide-1) — Incretin & Satiety
- Source: L-cells of distal ileum and colon (same as PYY)
- When released: After nutrient ingestion (especially carbohydrates and fats)
- Key effects:
- ↑ Insulin secretion (glucose-dependent) — the incretin effect
- ↓ Glucagon secretion
- ↓ Gastric emptying (slows GI transit)
- Acts on hypothalamus → ↓ appetite (satiety)
- Clinical pearl: GLP-1 receptor agonists (semaglutide, liraglutide) exploit these effects for T2DM and obesity
🪸 Leptin — Long-Term Adiposity Signal
- Source: Adipocytes (white adipose tissue); proportional to fat mass
- Mechanism: Binds receptors in arcuate nucleus → inhibits NPY/AgRP neurons + activates POMC/CART neurons → ↓ appetite, ↑ energy expenditure
- Key point: Long-term regulation (days–weeks); not meal-to-meal
- In obesity: High leptin levels but leptin resistance (analogous to insulin resistance)
- Starvation: ↓ Fat mass → ↓ leptin → ↑ NPY → ↑ hunger + ↓ metabolic rate + ↓ reproductive axis (amenorrhea)
📈 Hunger/Satiety Hormone Summary
| Hormone | Source | Released When | Effect on Appetite | Mechanism |
|---|---|---|---|---|
| Ghrelin | Gastric fundus (X/A cells) | Fasting / pre-meal | ↑ Hunger | Stimulates NPY/AgRP neurons |
| Peptide YY | Ileum/colon L-cells | Post-meal (fat/protein) | ↓ Appetite | Inhibits NPY/AgRP neurons |
| GLP-1 | Ileum/colon L-cells | Post-meal (CHO/fat) | ↓ Appetite | Hypothalamic satiety + ↑ insulin |
| Leptin | Adipocytes | Proportional to fat mass | ↓ Appetite | Inhibits NPY/AgRP; activates POMC |
| CCK | I-cells (duodenum) | Fat + protein in duodenum | ↓ Appetite | Vagus nerve → brain; also slows gastric emptying |
| Insulin | Pancreatic β-cells | Post-meal (glucose) | ↓ Appetite | Crosses BBB → inhibits NPY neurons |
- Ghrelin = the only hunger-stimulating gut hormone tested on Step 1. All other gut hormones (PYY, GLP-1, CCK) reduce appetite.
- In obesity: leptin is HIGH (more fat = more leptin) but there is leptin resistance — do not say leptin is low in obesity.
- After bariatric surgery, ghrelin falls and PYY/GLP-1 rise — mechanistically explaining reduced appetite post-surgery.
▼ Salivary Gland Anatomy & Composition
⭐ Saliva is produced at ~1.5 L/day; it lubricates, begins starch digestion, and provides antimicrobial protection.
🧞 Three Major Salivary Glands
| Gland | Type | Primary Secretion | Key Enzyme/Protein | % of Total Saliva |
|---|---|---|---|---|
| Parotid | Purely serous | Watery, enzyme-rich | α-amylase (ptyalin) | ~25% |
| Submandibular | Mixed (serous + mucous) | Serous + mucus | α-amylase + mucin | ~70% |
| Sublingual | Predominantly mucous | Thick, lubricating | Mucin (mucus glycoproteins) | ~5% |
🧪 Acinar Cells vs. Ductal Cells — Two-Stage Model
Saliva production occurs in two stages:
- Stage 1 — Acinar cells (primary secretion): Produce an isotonic fluid similar to plasma in electrolyte composition (plasma-like Na+, K+, Cl⁻, HCO3⁻)
- Stage 2 — Striated duct cells (modification):
- Na+ is actively reabsorbed (not permeable to water → tubular fluid becomes hypotonic)
- K+ is actively secreted
- HCO3⁻ is secreted (relative HCO3⁻ excess vs. plasma)
- Cl⁻ is reabsorbed
Net result: Final saliva is hypotonic to plasma, with ↑ K+, ↑ HCO3⁻, and ↓ Na+, ↓ Cl⁻ compared to plasma.
📈 Flow Rate & Tonicity Relationship
- Low flow rate: More time in duct for Na+ reabsorption → maximally hypotonic saliva; K+ very high
- High flow rate: Less modification time → saliva approaches isotonicity (more plasma-like); K+ concentration decreases slightly but remains above plasma
- Key rule: Saliva is always hypotonic to plasma, regardless of flow rate
- Na+ and K+ relationship with flow rate:
- Na+ ↑ as flow rate ↑ (more plasma-like at high flow)
- K+ ↓ slightly as flow rate ↑ (still always > plasma)
- Saliva has higher K+ and higher HCO3⁻ than plasma — reversed from what you might expect!
- Saliva has lower Na+ and lower Cl⁻ than plasma
- Saliva is always hypotonic to plasma (even at high flow rates)
- In Sjögren's syndrome (↓ saliva) → dry mouth, ↓ dental protection, ↓ antimicrobial IgA → ↑ dental caries
▼ Autonomic Control of Salivary Secretion
⭐ Parasympathetics are the dominant controller of sustained salivary flow; both ANS divisions stimulate secretion but via different mechanisms and timescales.
🧠 Parasympathetic Control (Primary)
- Cranial nerves:
- CN IX (glossopharyngeal) → parotid gland (via otic ganglion)
- CN VII (facial) → submandibular and sublingual glands (via submandibular ganglion)
- Neurotransmitters: ACh (M3 receptors) and VIP (vasoactive intestinal peptide)
- Effect: Sustained, large-volume watery secretion; vasodilation of gland blood vessels
- Mechanism (ACh): IP3/Ca2+ pathway → ↑ Cl⁻ channel opening → water follows osmotically
- Atropine: Blocks muscarinic receptors → dry mouth (xerostomia)
🧰 Sympathetic Control (Secondary)
- Origin: T1–T3 preganglionic → superior cervical ganglion → postganglionic fibers to glands
- Neurotransmitter: Norepinephrine (NE) → β-adrenergic receptors (primarily)
- Effect:
- Initial brief increase in saliva from myoepithelial cell contraction (squeezes pre-formed secretion)
- Followed by vasoconstriction → reduced blood flow → cessation of secretion (dry mouth during stress)
- Promotes protein-rich, viscous secretion (mucus)
- Bottom line: Sympathetics produce small volume, viscous secretion; parasympathetics produce large volume, watery secretion
⚗️ Hormonal Modification of Saliva
| Hormone | Effect on Salivary Ducts | Net Effect on Saliva |
|---|---|---|
| ADH (vasopressin) | ↑ H2O reabsorption from ducts | More concentrated saliva (↓ volume, ↑ solute concentration) |
| Aldosterone | ↑ Na+ reabsorption + ↑ K+ secretion in ducts | Even lower salivary Na+; higher K+ (similar to effect on renal tubule) |
Note: Aldosterone acts on salivary ducts the same way it acts on renal collecting ducts — a useful Step 1 parallel to remember.
- Students frequently write "vagus nerve" for salivary gland control. This is WRONG.
- Salivary glands are controlled by CN VII (facial) and CN IX (glossopharyngeal) — NOT CN X (vagus)
- The vagus controls most thoracic and abdominal viscera, but not the salivary glands
- Parotid: CN IX via otic ganglion | Submandibular + sublingual: CN VII via submandibular ganglion
- PSNS = sustained, watery saliva (ACh + VIP); SNS = brief, viscous blip then cessation
- Atropine → xerostomia (dry mouth) — blocks M3 receptors on acinar cells
- Aldosterone effect on salivary ducts mimics renal collecting duct (↑ Na+ reabsorption, ↑ K+ secretion)
- Salivary HCO3⁻ neutralizes gastric acid in the esophagus (protective)
🧠 Testing Your Understanding!
Testing Your Understanding — LO 1, Question 1
A researcher administers a compound that selectively blocks NPY/AgRP neurons in the hypothalamic arcuate nucleus. Predict what happens to appetite and energy balance. Which hormones would be most affected in their ability to regulate food intake?
Consider: What normally activates vs. inhibits NPY neurons? Think about ghrelin vs. leptin/PYY. What would chronic blockade do to body weight over time?
Blocking NPY/AgRP neurons removes the primary hunger-promoting circuit in the arcuate nucleus. NPY normally stimulates food intake, decreases energy expenditure, and promotes fat storage. Blocking it would: (1) reduce basal hunger drive, (2) blunt the hunger response to ghrelin (which normally acts by activating NPY neurons), (3) not affect the satiety response to leptin/PYY/GLP-1 (which work by inhibiting NPY neurons — so there would be less to inhibit). Net result: chronically decreased food intake and progressive weight loss.
Testing Your Understanding — LO 1, Question 2
A patient with primary aldosteronism (Conn's syndrome) — chronically elevated aldosterone — undergoes salivary testing. Compare the expected salivary electrolyte composition to that of a healthy person. Explain the mechanism.
Consider: How does aldosterone act on the renal collecting duct? Does it have the same effect on salivary ducts? What happens to Na+ and K+ concentrations in the final saliva?
Aldosterone acts on salivary duct cells identically to how it acts on the renal collecting duct: it upregulates epithelial Na+ channels (ENaC) to increase Na+ reabsorption, and Na+/K+-ATPase to increase K+ secretion into the duct lumen. In Conn's syndrome, excess aldosterone would maximally drive this exchange, resulting in saliva with even less Na+ and more K+ than normal. This is an important Step 1 clinical parallel — aldosterone's effects are not kidney-specific.
LO 2 — Esophageal & Gastric Secretory Products
Official LOs 5–6 · HoyaDocs GI Block
- LO 5: LIST the types of esophageal and gastric secretory products
- LO 6: DESCRIBE the functions of the gastric exocrine, endocrine, and paracrine products (including HCl mechanism, parietal cell products, and mucosal protection)
▼ Esophageal Secretory Products
⭐ The esophagus is primarily a conduit, not a digestive organ. Its secretory products are limited and focused on lubrication and mucosal protection.
📈 Esophageal Secretory Products — Master List
| Secretory Product | Source | Function |
|---|---|---|
| Mucus | Esophageal mucous glands (submucosal, throughout esophagus) | Lubricates food bolus passage; thin layer of protection against mild acid reflux |
| Mucus (cardiac type) | Cardiac glands (at upper esophagus near pharynx and near gastroesophageal junction) | Alkaline mucus secretion — extra protection near the GEJ where acid reflux risk is highest |
| Swallowed saliva (HCO3⁻-rich) | Salivary glands (not esophageal, but protective in esophagus) | Neutralizes refluxed gastric acid; clearance of acid after reflux events ("acid clearance") |
The esophagus has NO digestive enzymes and NO acid secretion of its own. It produces only mucus for lubrication and protection.
💉 Factors Reducing Esophageal Protection
- ↓ Salivary flow (e.g., Sjögren's, anticholinergics, radiation) → less HCO3⁻ available to neutralize reflux → ↑ esophageal acid exposure
- GERD: Repeated acid reflux overwhelms mucus barrier → esophageal mucosa injury → heartburn → Barrett's esophagus (intestinal metaplasia of esophageal squamous epithelium) if chronic
- Lower esophageal sphincter (LES) dysfunction: Not a secretory issue, but the primary defense against reflux reaching the esophageal mucosa
- Esophageal mucosa = stratified squamous epithelium — has NO mucus-secreting cells on the surface (only submucosal glands) and no alkaline bicarbonate surface coat. Very vulnerable to acid.
- Gastric mucosa = simple columnar epithelium with surface mucous cells secreting a thick alkaline gel (pH gradient from pH 2 in lumen to pH ~7 at cell surface).
- Duodenal mucosa = protected by Brunner's glands (alkaline mucus) + pancreatic HCO3⁻ + bile.
- This explains why GERD damages the esophagus first — it lacks the gastric-type mucosal armor.
▼ Gastric Gland Cell Types
⭐ The gastric gland is a tubular structure in the gastric mucosa containing specialized cells, each with distinct secretory products essential for digestion.
📈 Complete Cell Type Reference Table
| Cell Type | Location in Gland | Secretory Product(s) | Function / Key Details | Stimulated By |
|---|---|---|---|---|
| Surface Mucous Cells | Gastric surface + pit | Alkaline mucus | Forms protective gel layer (pH 6–7 at surface despite luminal pH 2); first line barrier | Prostaglandins, ACh |
| Mucous Neck Cells | Neck of gastric gland | Soluble mucus | Thinner mucus; also progenitor cells for mucosal renewal | ACh |
| Parietal Cells (Oxyntic) | Upper to mid gland body | HCl + Intrinsic Factor (IF) | HCl: activates pepsin, kills bacteria, denatures proteins. IF: essential for B12 absorption in terminal ileum | ACh (M3), Gastrin (CCK2), Histamine (H2) |
| Chief Cells (Zymogenic) | Base of gland | Pepsinogen I & II + Gastric Lipase | Pepsinogen: activated by HCl → pepsin (endopeptidase). Gastric lipase: begins fat digestion | ACh, secretin, ↓ pH |
| G Cells | Pyloric antrum | Gastrin | Stimulates parietal + chief cells; promotes gastric motility; trophic to GI mucosa | Peptides/AAs in lumen, vagal ACh, stomach distension |
| D Cells | Throughout (antrum + fundus) | Somatostatin | Paracrine inhibitor of G cells and parietal cells; the "off switch" for acid secretion | ↓ Luminal pH (<3), fat, secretin |
| ECL Cells (Enterochromaffin-like) | Fundus / oxyntic gland | Histamine + Serotonin | Histamine amplifies parietal cell HCl secretion (H2 receptor); stimulated by gastrin | Gastrin, ACh |
🔬 Parietal Cell — The Most Tested Gastric Cell
- Two unique products: HCl and Intrinsic Factor — only cell that makes IF
- Stimulated by THREE pathways (all must be known):
- ACh via M3 (muscarinic) receptors → IP3/Ca2+ → ↑ H+/K+-ATPase
- Gastrin via CCK-B (CCK2) receptors → IP3/Ca2+ pathway (also stimulates ECL cells)
- Histamine via H2 receptors → cAMP/PKA → ↑ H+/K+-ATPase (most potent direct stimulator)
- Clinical importance of IF: Autoimmune destruction of parietal cells (autoimmune atrophic gastritis) → ↓ IF → B12 malabsorption → pernicious anemia (megaloblastic)
- Pernicious anemia = autoimmune destruction of parietal cells → no IF → no B12 absorption (terminal ileum requires IF-B12 complex)
- Zollinger-Ellison syndrome = gastrinoma (G-cell tumor) → massively elevated gastrin → hyperstimulated parietal cells → severe peptic ulcer disease + diarrhea
- ECL cells are the intermediary: gastrin → ECL → histamine → parietal cell (this is why H2 blockers can partially reduce acid even when gastrin is elevated)
- Chief cells produce pepsinogen (inactive zymogen) — HCl activates it to pepsin at pH < 2
▼ HCl Secretion Mechanism (Parietal Cell)
⭐ The parietal cell uses carbonic anhydrase and the H+/K+-ATPase (proton pump) to secrete H+ at concentrations 3 million times higher than blood.
⚗️ Step-by-Step HCl Secretion
- CO2 + H2O → H2CO3 (catalyzed by carbonic anhydrase inside parietal cell)
- H2CO3 → H+ + HCO3⁻ (spontaneous dissociation)
- H+ is pumped into the gastric lumen via H+/K+-ATPase (antiport — simultaneously imports K+)
- HCO3⁻ exits the basolateral side via HCO3⁻/Cl⁻ antiporter → enters blood → "alkaline tide"
- Cl⁻ (imported from blood) then exits into the gastric lumen through apical Cl⁻ channels → combines with H+ to form HCl
CO2 + H2O →CA H2CO3 → H+ + HCO3⁻
H+ → [H+/K+-ATPase] → gastric lumen
HCO3⁻ → [HCO3⁻/Cl⁻ antiport] → blood (alkaline tide)
Cl⁻ → [apical Cl⁻ channel] → gastric lumen
Net: secretion of HCl into stomach lumen
⚡ Rate-Limiting Step
The H+/K+-ATPase (proton pump) is the rate-limiting step. This is why PPIs (which block H+/K+-ATPase) are so effective at reducing gastric acid — they target the final, obligate step.
🌊 The Alkaline Tide
- Definition: The rise in blood (and urine) pH that occurs after a meal
- Mechanism: For every H+ pumped into the stomach, one HCO3⁻ is secreted into the blood via the HCO3⁻/Cl⁻ exchanger
- Magnitude: Significant — can cause postprandial alkaline urine ("alkaline tide" measurable in urine)
- Teleological logic: The body is "preparing" alkaline buffering capacity to neutralize food bolus entering the duodenum (secretin later triggers pancreatic HCO3⁻ release)
- PPIs (e.g., omeprazole, pantoprazole): Irreversibly block H+/K+-ATPase (the proton pump itself). Most effective. Must be taken before meals (need active proton pumps). Requires acid activation (prodrug).
- H2 blockers (e.g., ranitidine, cimetidine, famotidine): Block H2 receptors on parietal cells → reduce cAMP → less proton pump activity. Less effective than PPIs because other pathways (ACh, gastrin) can still stimulate the pump.
- Key: H2 blockers block histamine signaling; PPIs block the pump itself — they work at different levels of the same pathway.
- Rate-limiting step: H+/K+-ATPase (proton pump)
- Carbonic anhydrase inhibitors (acetazolamide) can ↓ HCl secretion — tested in glaucoma/altitude sickness context
- Alkaline tide: Post-meal rise in blood HCO3⁻ due to parietal cell HCO3⁻/Cl⁻ exchange
- In pyloric stenosis (projectile vomiting): lose HCl → hypochloremic metabolic alkalosis + hypokalemia (renal K+ wasting to preserve Na+ when Cl⁻ is low)
▼ Mucosal Barrier & Gastric Protection
⭐ The gastric mucosa protects itself from its own acid via a multilayer defense system.
🛡️ Layers of Gastric Defense
- Mucus-bicarbonate barrier: Surface mucous cells secrete thick alkaline mucus gel; trapped HCO3⁻ creates a pH gradient (pH ~6–7 at cell surface, pH ~2 in lumen)
- Tight junctions: Prevent back-diffusion of H+ into mucosa
- Mucosal blood flow: Delivers HCO3⁻ and removes acid that penetrates; prostaglandins (PGE2, PGI2) maintain mucosal blood flow
- Rapid cell turnover: Gastric epithelium renews every 3–5 days
💊 NSAIDs & Mucosal Injury
- Mechanism: COX inhibition → ↓ prostaglandin synthesis → ↓ mucus/HCO3⁻ secretion + ↓ mucosal blood flow → erosions and ulcers
- Prevention: Misoprostol (PGE1 analog) to restore mucosal protection; or take with food; or use selective COX-2 inhibitors (celecoxib)
- NSAIDs also cause ulcers systemically via direct topical acid damage even at non-gastric sites when absorbed
- Anterior duodenal ulcer → perforation → free air under diaphragm (pneumoperitoneum)
- Posterior duodenal ulcer → erodes gastroduodenal artery → massive upper GI bleed
- Most common location for PUD: first part of duodenum (DU > GU overall in frequency)
🧠 Testing Your Understanding!
Testing Your Understanding — LO 2, Question 1
A patient with autoimmune atrophic gastritis presents with profound fatigue, macrocytic anemia, and neurological symptoms including subacute combined degeneration. What specific cell is being destroyed, what two products are lost, and how does each loss contribute to the clinical picture?
Consider: What does each parietal cell product do? Why would HCl loss alone not cause neurological symptoms? What extra step is needed for B12 absorption?
Loss of HCl: achlorhydria causes hypergastrinemia (no acid feedback inhibition of G cells), impaired protein digestion, and increased susceptibility to GI infections. HCl loss alone does not cause neurological symptoms. Loss of Intrinsic Factor: IF is the glycoprotein secreted exclusively by parietal cells that binds dietary B12 (cobalamin) and enables its absorption at the terminal ileum (cubam receptor). Without IF, B12 cannot be absorbed → B12 deficiency → megaloblastic anemia (macrocytosis, hypersegmented neutrophils) AND subacute combined degeneration of the spinal cord (demyelination of dorsal columns + lateral corticospinal tracts → loss of vibration/proprioception and weakness). This is pernicious anemia.
Testing Your Understanding — LO 2, Question 2
Explain why, after a large meal, the urine becomes transiently more alkaline (the "alkaline tide"). Trace the specific molecular events from CO2 in the parietal cell to HCO3⁻ in the blood.
Consider: What happens to HCO3⁻ after H+ is secreted? Which transporter is responsible? Where does this HCO3⁻ go?
Inside the parietal cell: CO2 + H2O → (carbonic anhydrase) → H2CO3 → H+ + HCO3⁻. The H+ is pumped into the gastric lumen by H+/K+-ATPase. The HCO3⁻ exits the basolateral side via the HCO3⁻/Cl⁻ antiporter (exchanges intracellular HCO3⁻ for extracellular Cl⁻). This HCO3⁻ enters the portal blood → raises blood pH → kidneys excrete more HCO3⁻ in urine → alkaline urine after meals. This phenomenon (the "alkaline tide") is measurable and proportional to the amount of acid secreted. The Cl⁻ imported from blood then exits apically into the stomach lumen with H+ to form HCl.
LO 3 — Gastric Acid Regulation, H. pylori & Drug Targets
Official LOs 7–11 · HoyaDocs GI Block
- LO 7: STATE the role of the nervous system in affecting gastric secretion (cephalic/gastric/intestinal phases; vagal control)
- LO 8: DESCRIBE the mechanism involved in the generation of gastric acid; IDENTIFY the rate-limiting step; DESCRIBE how H. pylori can cause gastric ulcerations (see also Tab 2 for HCl mechanism detail)
- LO 9: DESCRIBE why drugs inhibiting H2 receptors and certain molecular pumps (H+/K+-ATPase) inhibit HCl secretion
- LO 10: PREDICT the effect of vagotomy on gastric and overall GI function
- LO 11: PREDICT the consequences of the failure to secrete gastric acid (achlorhydria)
▼ Three Phases of Gastric Secretion
⭐ Gastric acid secretion is coordinated in three overlapping phases: cephalic (30–40% of acid), gastric (50–60%), and intestinal (5–10%).
🧠 Phase 1 — Cephalic Phase
- Trigger: Sight, smell, taste, thought, or anticipation of food — before food enters the stomach
- Pathway: Cerebral cortex/hypothalamus → dorsal vagal nucleus → vagus nerve (CN X) → postganglionic neurons → gastric enteric nervous system
- Mediators (vagal):
- Direct ACh on parietal cells (↑ HCl)
- ACh on G cells (↑ gastrin → ↑ HCl)
- ACh inhibits D cells → ↓ somatostatin → allows more gastrin release
- GRP (gastrin-releasing peptide) from vagal nerve terminals → G cells → ↑ gastrin
- Contribution: ~30–40% of total acid response to a meal
- Clinical: Highly vagotomized patients (truncal vagotomy) lose this phase → reduced acid; also why sham feeding studies show acid response before any food is ingested
🥕 Phase 2 — Gastric Phase
- Trigger: Food actually in the stomach — distension, proteins/amino acids, ↑ pH (food buffers acid)
- Mediators:
- Stomach distension → vagovagal reflex + local ENS → ↑ ACh → ↑ HCl
- Peptides and amino acids in antrum → stimulate G cells → ↑ gastrin → ↑ HCl
- ↓ Luminal pH (food temporarily buffers acid) → relieves inhibition of G cells → ↑ gastrin
- Contribution: ~50–60% of total acid output
- Feedback inhibition: When luminal pH <3, somatostatin from D cells inhibits G cells → prevents runaway acid production
🥘 Phase 3 — Intestinal Phase
- Trigger: Chyme entering the duodenum
- Initial stimulation: Amino acids/peptides in duodenum stimulate intestinal G cells → brief gastrin rise
- Predominant effect = INHIBITION of gastric acid:
- Acidic chyme (pH <4.5) → S-cells release secretin → inhibits gastrin release + ↓ HCl + ↑ pancreatic HCO3⁻
- Fat + protein in duodenum → I-cells release CCK → inhibits gastric emptying (enterogastric reflex), ↑ pancreatic enzymes, ↑ gallbladder contraction
- Fat + protein → K-cells release GIP → inhibits gastric acid + ↑ insulin secretion
- Neural: enterogastric reflex (duodenal distension/acid/fat → inhibitory reflexes → ↓ gastric emptying and acid)
- Contribution: ~5–10% of total acid (and mostly inhibitory)
📈 Three Phases — At a Glance
| Phase | Trigger | Primary Mediators | % Acid Secretion | Net Effect |
|---|---|---|---|---|
| Cephalic | Sight/smell/thought of food | Vagus → ACh + GRP → gastrin | 30–40% | ↑ HCl |
| Gastric | Food in stomach (distension, AAs) | ACh, Gastrin, Histamine | 50–60% | ↑ HCl (dominant phase) |
| Intestinal | Chyme in duodenum | Secretin, CCK, GIP; enterogastric reflex | 5–10% | ↓ HCl (mainly inhibitory) |
- The cephalic phase is 100% vagal (CN X). Vagotomy eliminates the cephalic phase.
- The gastric phase also has a vagal component (vagovagal reflex), but gastrin and local ENS reflexes can maintain it even after vagotomy.
- The intestinal phase is largely hormonal (secretin, CCK, GIP) — vagotomy has minimal effect on it.
▼ Stimulators & Inhibitors of HCl Secretion
⭐ Three potent stimulators (histamine, acetylcholine, gastrin) converge on the parietal cell; multiple inhibitors act to turn off acid production.
⇧ Stimulators of HCl
| Stimulator | Source | Receptor on Parietal Cell | Second Messenger | Potency |
|---|---|---|---|---|
| Histamine | ECL cells (gastric fundus) | H2 receptor | cAMP → PKA | Most potent direct stimulator |
| Acetylcholine (ACh) | Vagal + ENS neurons | M3 (muscarinic) | IP3/Ca2+ | Moderate |
| Gastrin | G cells (antrum) | CCK-B (CCK2) | IP3/Ca2+ | Moderate (also via ECL→histamine) |
These three stimulators act synergistically — blocking one (e.g., H2 blockers) reduces the effectiveness of the others. This is the basis for combination therapy.
⇩ Inhibitors of HCl
- Somatostatin (D cells): Stimulated by low luminal pH (<3), fat, secretin → inhibits G cells (↓ gastrin) and parietal cells directly; the primary "off switch"
- Secretin (S cells): Released when duodenal pH <4.5; inhibits gastrin release + gastric acid; stimulates pancreatic HCO3⁻
- CCK (I cells): Released by fat + protein; inhibits gastric emptying; weak direct acid inhibition
- GIP (K cells): Released by fat + AAs + glucose; inhibits gastric acid; strong incretin effect (↑ insulin)
- Prostaglandins (PGE2, PGI2): Inhibit parietal cell cAMP → ↓ HCl; maintain mucosal blood flow; hence NSAIDs (block PG synthesis) → ↑ acid injury
Histamine · ACh · Gastrin — all stimulate parietal cell HCl secretion. All three are needed together for maximal acid output.
▼ H. pylori Pathophysiology
⭐ Helicobacter pylori is a gram-negative microaerophilic rod that colonizes the gastric antrum and is the #1 cause of peptic ulcer disease worldwide.
🧰 H. pylori Virulence Mechanisms
- Urease: Hydrolyzes urea → NH3 (ammonia) + CO2 → ammonia neutralizes local H+ → creates protective alkaline microenvironment around the bacteria; also directly toxic to epithelium
- Mucinase: Degrades mucin in the protective mucus gel → disrupts the mucus-bicarbonate barrier → allows acid and pepsin direct access to epithelium
- CagA protein (cytotoxin-associated gene A): Virulence factor injected into host epithelial cells → promotes inflammation, cellular proliferation, and increased cancer risk
- VacA toxin: Forms pores in epithelial cell membranes → vacuolation and cell death
- Phospholipase A: Degrades phospholipid layer of mucus barrier
📎 Consequences of H. pylori Infection
- Type B (antral) gastritis: Chronic active inflammation of antrum → damages D cells (↓ somatostatin) → G cells disinhibited → ↑ gastrin → ↑ HCl → duodenal ulcers
- Peptic ulcer disease (PUD): DU 90%, GU 70–80% H. pylori positive
- Gastric ulcers: H. pylori can directly infect gastric corpus → loss of parietal cell mass → achlorhydria → hypergastrinemia
- Gastric cancer: Chronic H. pylori gastritis → intestinal metaplasia → dysplasia → adenocarcinoma (WHO Class I carcinogen). CagA+ strains have higher cancer risk.
- MALT lymphoma: H. pylori-driven chronic antigenic stimulation of gastric mucosa-associated lymphoid tissue → B-cell lymphoma; can regress with H. pylori eradication!
⚗️ Diagnosis and Treatment
- Urea breath test: Patient ingests 13C-labeled urea; H. pylori urease cleaves it → 13CO2 detected in exhaled breath. Non-invasive, best for confirming eradication.
- Stool antigen test: Detects H. pylori antigens in feces. Non-invasive screening.
- CLO test (biopsy): Rapid urease test on endoscopic biopsy sample
- Serology: IgG antibodies — doesn't distinguish current vs. past infection; not useful for eradication confirmation
- Treatment — Triple Therapy: PPI + clarithromycin + amoxicillin (or metronidazole) x 7–14 days
- Quadruple therapy (if resistance): PPI + bismuth + metronidazole + tetracycline
- H. pylori infection of the antrum (most common) → destroys D cells → ↓ somatostatin → ↑ gastrin → ↑ acid → duodenal ulcers
- H. pylori infection of the corpus (body/fundus) → destroys parietal cells → ↑ gastrin (from loss of feedback) but ↓ HCl output → gastric ulcers + gastric cancer risk
- So the same organism can cause opposite acid effects depending on which part of the stomach is infected. The clinical manifestation (DU vs. GU) depends on the distribution of infection.
▼ Pharmacological Targets for Reducing Gastric Acid
⭐ Multiple drug classes target different points in the gastric acid secretion pathway — from blocking signaling to neutralizing existing acid.
💊 Drug Class Comparison Table
| Drug Class | Example(s) | Mechanism | Target | Efficacy | Key Notes |
|---|---|---|---|---|---|
| PPIs | Omeprazole, pantoprazole, lansoprazole | Irreversibly block H+/K+-ATPase (proton pump) | Parietal cell apical membrane | Highest | Prodrug activated by acid; must be active (eating = pumps active); irreversible — new pumps needed for recovery |
| H2 Blockers | Ranitidine, cimetidine, famotidine | Competitively block H2 receptor → ↓ cAMP → ↓ pump activity | H2 receptor on parietal cell | Moderate | Cimetidine inhibits CYP450 (drug interactions); ranitidine withdrawn (NDMA contamination); tolerance develops |
| Antacids | Ca(OH)2, Mg(OH)2, Al(OH)3, NaHCO3 | Neutralize existing acid (chemical buffering) | Gastric lumen | Low (symptomatic only) | Mg(OH)2 → diarrhea; Al(OH)3 → constipation; Ca(OH)2 → rebound acid (milk-alkali syndrome) |
| Misoprostol | Misoprostol | PGE1 analog → ↓ cAMP in parietal cells + ↑ mucus/HCO3⁻ secretion | EP receptor on parietal cell + mucosal cells | Moderate (protective) | Used for NSAID-induced ulcer prophylaxis; causes uterine contractions (used for abortion/cervical ripening) |
| Sucralfate | Sucralfate | Forms protective paste over ulcer crater; binds pepsin | Ulcer site (physical barrier) | Low-moderate | Does not reduce acid; works in acidic environment; must avoid antacids simultaneously |
📌 Vagotomy — Surgical Acid Reduction
- Truncal vagotomy: Cuts both vagal trunks → eliminates cephalic phase and vagal gastric phase → significant ↓ acid; but also impairs gastric emptying → requires drainage procedure (pyloroplasty)
- Highly selective vagotomy (parietal cell vagotomy): Denervates only acid-secreting mucosa; spares antrum (no gastric stasis); no drainage procedure needed; lower ulcer recurrence than truncal
- Largely replaced by PPIs for medical management, but still relevant surgically for refractory cases
- PPIs are irreversible — recovery requires synthesis of new H+/K+-ATPase (takes ~18 h); H2 blockers are competitive/reversible
- Cimetidine inhibits CYP1A2, CYP2C9, CYP2D6 → multiple drug interactions (warfarin, theophylline); also causes gynecomastia (anti-androgen effect)
- PPIs long-term: ↑ risk of C. difficile, community-acquired pneumonia, hypomagnesemia, osteoporosis (↓ Ca2+ absorption)
- Misoprostol is used both for ulcer prophylaxis (with NSAIDs) AND as an abortifacient — know both uses
🧠 Testing Your Understanding!
Testing Your Understanding — LO 3, Question 1
A medical student is studying a famous experiment in which a subject merely looks at and smells food without actually eating it (sham feeding). Remarkably, gastric acid secretion increases significantly. Which neural pathway mediates this, and what would happen if the subject had previously undergone a truncal vagotomy?
Consider: Which phase of gastric secretion is initiated by sight/smell of food? Which cranial nerve is the main conductor? What percentage of total acid does this phase contribute, and what would eliminating it do?
The cephalic phase is triggered by cortical/hypothalamic responses to the sight, smell, and thought of food. The signal travels from the dorsal vagal nucleus via CN X to the stomach, where it: (1) directly stimulates parietal cells via ACh (M3), (2) stimulates G cells via GRP → ↑ gastrin, and (3) inhibits D cells → ↓ somatostatin → further disinhibiting G cells. The cephalic phase accounts for ~30–40% of total acid output from a meal. After truncal vagotomy, the cephalic phase is completely eliminated, so sham feeding would produce little to no gastric acid response. The remaining acid secretion (gastric and intestinal phases) would be partially preserved via local ENS reflexes and hormonal pathways.
Testing Your Understanding — LO 3, Question 2
A 45-year-old man is found to have H. pylori antral gastritis. Explain the chain of events from H. pylori colonizing the antrum to the development of a duodenal ulcer, naming each molecular step.
Consider: H. pylori → effect on D cells → effect on somatostatin → effect on G cells → gastrin → parietal cells → acid in duodenum → mucosal damage.
H. pylori's urease and mucinase disrupt the antral mucosa, inflaming and destroying D cells (which normally secrete somatostatin as a paracrine inhibitor of G cells). With less somatostatin, antral G cells are disinhibited → chronically elevated gastrin → maximal stimulation of parietal cells → high acid output. This acid overwhelms the duodenal mucosal defenses (Brunner's glands and bicarbonate secretion cannot keep up) → duodenal mucosal erosion → duodenal ulcer. The #1 location is the first part of the duodenum (duodenal bulb). Treatment: H. pylori eradication with triple therapy reverses the elevated gastrin and allows ulcer healing.
LO 4 — Pancreatic & Intestinal Secretions
Official LOs 12–13 · HoyaDocs GI Block
- LO 12: LIST the electrolytes and enzymes secreted by the pancreas during digestion; IDENTIFY the hormonal factors controlling secretions of the exocrine pancreas; DESCRIBE the mechanisms involved in stimulating the secretion of these hormones
- LO 13: STATE the exocrine and endocrine secretions of the small intestine; STATE neuropeptides and other factors affecting secretion by the small intestine
▼ Pancreatic Cell Types & Products
⭐ The exocrine pancreas produces ~1.5 L/day of alkaline, enzyme-rich juice. Two distinct cell populations handle enzymes and electrolytes separately.
🧪 Acinar Cells vs. Centroacinar Cells
| Cell Type | Location | Primary Secretion | Stimulated By | Key Notes |
|---|---|---|---|---|
| Acinar cells | Periphery of acinus | Digestive enzymes (as zymogens) | CCK (I-cells), ACh (vagal) | Protein-rich secretion; enzymes stored as zymogen granules |
| Centroacinar cells | Center of acinus + ducts | Bicarbonate-rich, enzyme-poor fluid | Secretin (S-cells), VIP | CFTR channels; cAMP-mediated HCO3⁻ secretion; neutralizes duodenal acid |
Pancreatic juice = acinar enzyme component + centroacinar/ductal HCO3⁻ component mixed together
🥜 Pancreatic Enzyme Repertoire
| Enzyme | Precursor Form | Activated By | Substrate | Notes |
|---|---|---|---|---|
| Trypsin | Trypsinogen | Enterokinase (brush border) | Proteins (endopeptidase) | Master activator — activates all other zymogens |
| Chymotrypsin | Chymotrypsinogen | Trypsin | Proteins (aromatic AAs) | |
| Elastase | Proelastase | Trypsin | Elastin, proteins | |
| Carboxypeptidases | Procarboxypeptidases | Trypsin | C-terminal AAs (exopeptidase) | |
| Pancreatic Amylase | Active (no zymogen) | N/A — already active | Starch (α-1,4 linkages) | Same function as salivary amylase; active in duodenum/jejunum |
| Pancreatic Lipase | Active (no zymogen) | Requires colipase (from pro-colipase activated by trypsin) | Triglycerides → 2-monoglyceride + 2 FFAs | Needs alkaline pH; works best at pH 7–8; bile salts displace lipase → colipase restores binding |
| Phospholipase A2 | Prophospholipase A2 | Trypsin | Phospholipids | Requires Ca2+; important in acute pancreatitis pathology |
| Cholesterol esterase | Active | N/A | Cholesterol esters | Requires bile salts for activity |
▼ Pancreatic Enzyme Activation Cascade
⭐ Pancreatic proteases are secreted as inactive zymogens to prevent autodigestion. Activation occurs in the duodenal lumen via a tightly controlled cascade.
▶ The Activation Cascade
Step 2: Trypsin activates ALL other zymogens:
Chymotrypsinogen → Chymotrypsin
Proelastase → Elastase
Procarboxypeptidase → Carboxypeptidase
Pro-colipase → Colipase (lipase cofactor)
Prophospholipase A2 → Phospholipase A2
Step 3: Colipase anchors lipase to lipid droplet → enables fat digestion
Key: Enterokinase is the trigger — it's not a pancreatic enzyme; it's a duodenal brush border enzyme. Enterokinase deficiency → protein malabsorption (cannot activate trypsin).
🛡️ Pancreatic Self-Protection
- Secretory trypsin inhibitor (SPINK1): Stored in zymogen granules with trypsinogen; inactivates any trypsin accidentally activated within the acinar cell
- Compartmentalization: Zymogens kept in membrane-bound granules until exocytosis
- pH: Pancreatic juice is alkaline (high HCO3⁻); proteases work best at neutral-alkaline pH, but autoactivation is minimized without enterokinase
🎯 Regulation of Pancreatic Secretion
| Stimulus | Hormone/Mediator | Effect on Pancreas |
|---|---|---|
| Acid chyme (pH <4.5) in duodenum | Secretin (S-cells) | ↑ HCO3⁻ secretion (centroacinar cells); ↓ enzyme secretion |
| Fat + protein in duodenum | CCK (I-cells) | ↑ Enzyme secretion (acinar cells); also potentiates secretin effect on HCO3⁻ |
| Cephalic/gastric phase | Vagus (ACh) | ↑ Enzyme secretion (acinar); minor HCO3⁻ increase |
| Somatostatin, sympathetics, glucagon | Various | ↓ Pancreatic secretion |
- Acute pancreatitis occurs when zymogens are activated within the pancreas (not in the duodenum)
- Causes: gallstone obstructing the pancreatic duct, alcohol (disrupts zymogen granules), hyperlipidemia, trauma
- Activated phospholipase A2 → fat necrosis + saponification → Ca2+ sequestration → hypocalcemia (Chvostek's sign, Trousseau's sign)
- Elastase → digests blood vessel walls → hemorrhagic pancreatitis → periumbilical bruising (Cullen's sign) or flank bruising (Grey Turner's sign)
- Enterokinase is the master trigger — brush border enzyme, not pancreatic
- Trypsin activates all other proteolytic zymogens (plus colipase and phospholipase A2)
- Lipase is active as secreted but requires colipase (activated by trypsin) to function in the presence of bile salts
- Amylase is unique: secreted in active form (no zymogen), not harmful to pancreas
- In cystic fibrosis: CFTR mutation → thick, viscous secretions → blocked pancreatic ducts → autodigestion → exocrine pancreatic insufficiency → fat malabsorption + steatorrhea
▼ Intestinal Secretions Overview
⭐ The small intestinal mucosa secretes fluid, ions, and protective substances via specialized cells in the crypts of Lieberkühn and Brunner's glands.
🧪 Crypts of Lieberkühn
- Location: Base of intestinal villi throughout the small and large intestine
- Function: Secrete isotonic fluid (NaCl + water) to lubricate and solubilize digested food for absorption; serve as progenitor cell niche
- Primary secretory mechanism: CFTR (Cl⁻ channel) at apical membrane → Cl⁻ secretion into lumen → Na+ follows paracellularly → water follows osmotically
- Stimulated by: cAMP (VIP, secretin), cGMP (heat-stable enterotoxins), Ca2+ (ACh, VIP at high doses)
⚗️ CFTR & Chloride Secretory Diarrhea
- Normal CFTR function: cAMP activates PKA → phosphorylates CFTR → opens Cl⁻ channel → Cl⁻ secretion → draws water into lumen
- Cholera toxin (V. cholerae): Permanently activates Gs (adenylate cyclase) → cAMP → massive CFTR activation → rice-water diarrhea (up to 20 L/day)
- E. coli heat-labile toxin (LT): Same mechanism as cholera — activates Gs via ADP-ribosylation
- E. coli heat-stable toxin (ST): Activates guanylate cyclase → ↑ cGMP → ↑ CFTR activity → secretory diarrhea
- Cystic fibrosis: Loss-of-function CFTR → thick mucus plugging intestinal glands → meconium ileus (newborn), distal intestinal obstruction syndrome (older children), fat malabsorption
▼ Intestinal Cell Types & Specialized Functions
⭐ Five specialized cell types in the small intestinal epithelium serve distinct roles in secretion, protection, and hormonal signaling.
🧰 Cell Type Summary
| Cell Type | Location | Secretion | Function | Step 1 Relevance |
|---|---|---|---|---|
| Goblet Cells | Throughout SI and colon; ↑ density distally | Mucin (mucus glycoproteins) | Lubricates epithelial surface; traps bacteria; barrier against digestive enzymes | Mucus-secreting; decreased in active IBD; increased in irritation |
| Paneth Cells | Base of crypts (small intestine only) | α-defensins (cryptdins), lysozyme, phospholipase A2, secretory IgA, zinc | Host defense — antimicrobial peptides control luminal bacteria; maintain crypt stem cell niche | Absent in colon. Paneth cell metaplasia in IBD = diagnostic clue. Zinc dependency notable. |
| Enteroendocrine Cells | Throughout SI and colon | Gastrin (G), CCK (I), Secretin (S), GIP (K), Motilin (M), Serotonin (EC cells), GLP-1/PYY (L) | Hormonal regulation of GI secretion, motility, and systemic metabolism | High-yield: know each cell type, location, stimulus, and effect |
| Absorptive Cells (Enterocytes) | Villi (tip to base) | Brush border enzymes (enterokinase, disaccharidases, peptidases) | Nutrient absorption; site of active Na+ absorption (Na+/K+-ATPase basolateral) | Enterokinase is here (activates trypsinogen); disaccharidase deficiency → osmotic diarrhea |
💉 Brunner's Glands (Submucosal Glands of the Duodenum)
- Location: Submucosa of the duodenum (only part of GI tract with submucosal glands)
- Products:
- Thick, alkaline mucus (HCO3⁻-rich) — primary role
- Urogastrone (EGF) — promotes mucosal cell proliferation
- Pepsinogen (minor)
- Function: Protects duodenal mucosa from the acid chyme entering from the stomach; neutralizes luminal acid immediately
- Stimulated by: Secretin (primary), vagal stimulation (ACh), ↓ luminal pH
- Inhibited by: Sympathetic stimulation (epinephrine → vasoconstriction → ↓ gland activity)
- Clinical pearl: Brunner's gland hyperplasia can cause duodenal polyposis; stress (↑ SNS tone) impairs Brunner's glands → contributes to stress ulcers
- Paneth cells are normally absent from the colon. Their presence in colon biopsies is called Paneth cell metaplasia and is a pathological finding associated with chronic mucosal injury (e.g., Crohn's disease, ulcerative colitis).
- Paneth cells secrete defensins (antimicrobial peptides) — mutations in defensin genes are associated with increased Crohn's disease risk.
- Do not confuse Paneth cells (in crypts, defense function) with Chief cells (in gastric glands, pepsinogen).
🧠 Testing Your Understanding!
Testing Your Understanding — LO 4, Question 1
A patient with cystic fibrosis presents as a newborn with failure to pass meconium (meconium ileus). As he grows older, he develops steatorrhea and fat-soluble vitamin deficiency despite a high-calorie diet. Trace the pathophysiology from the CFTR mutation to each of these GI complications.
Consider: CFTR in pancreatic ducts vs. intestinal crypts. What happens when pancreatic ducts are obstructed? Why would fat malabsorption lead to vitamin deficiency? Which vitamins are fat-soluble?
Meconium ileus: CFTR loss in intestinal epithelium → thick, desiccated intestinal mucus → meconium cannot be cleared → bowel obstruction at birth. Steatorrhea: CFTR in pancreatic ductal cells normally enables HCO3⁻-rich fluid to flush zymogens out; without CFTR, viscous secretions plug the ducts → autodigestion of pancreas → exocrine pancreatic insufficiency → no lipase/colipase reaching duodenum → triglycerides cannot be digested → steatorrhea (fatty, greasy stools). Fat-soluble vitamin deficiency: Fat absorption is required to carry vitamins A, D, E, K into the enterocyte. Fat malabsorption → ADEK deficiencies → night blindness (A), rickets/osteoporosis (D), hemolytic anemia (E), bleeding diathesis (K).
Testing Your Understanding — LO 4, Question 2
Explain why cholera causes such massive diarrhea (up to 20 L/day). What is the specific molecular target of cholera toxin, and why can't the cell "turn off" the signal?
Consider: What second messenger is involved? Which protein does cholera toxin modify, and how? What does CFTR do when maximally activated?
Cholera toxin enters intestinal epithelial cells and ADP-ribosylates the α-subunit of the stimulatory G protein (Gsα), preventing GTP hydrolysis. Normally, Gsα inactivates itself by hydrolyzing GTP to GDP; this modification locks it in the active (GTP-bound) form permanently. Gsα continuously activates adenylate cyclase → continuous cAMP production → PKA constitutively active → CFTR apical Cl⁻ channels fully open → massive Cl⁻ efflux into lumen → Na+ follows paracellularly → water follows osmotically → "rice water" secretory diarrhea. The diarrhea is isotonic and enormous because absorption continues (Na+-glucose co-transport) — this is why oral rehydration solution (ORS with glucose) is so effective: glucose drives Na+ absorption even while CFTR-mediated secretion is maximal.
LO 5 — Colonic Secretions & GI Hormone Master Table
Official LO 14 · HoyaDocs GI Block
- LO 14: STATE the factors affecting secretions in the colon and the significance of the secretions (includes GI hormone master table integration)
▼ Colonic Mucus Secretion
⭐ The colon secretes less fluid than the small intestine but maintains critical mucus and electrolyte secretion for fecal lubrication and protection.
🧞 Goblet Cells in the Colon
- Density: Goblet cells are more numerous in the colon than in the small intestine — the colon relies more on mucus-based protection than enzymatic processing
- Product: Mucin 2 (MUC2) — the major secreted mucin of the colon; forms a two-layer gel:
- Inner (sterile) layer: firmly attached to epithelium, bacteria-free
- Outer layer: loosely attached, inhabited by commensal bacteria
- Functions:
- Lubricates fecal matter for transit
- Barrier against bacterial invasion (inner layer is impenetrable to bacteria)
- Contains secretory IgA (from plasma cells) and antimicrobial peptides
- Stimulated by: PSNS (ACh via M3), ENS reflexes, local inflammatory mediators
- Inhibited by: SNS (epinephrine reduces mucus secretion)
📈 Colon vs. Small Intestine — Secretory Comparison
| Feature | Small Intestine | Colon |
|---|---|---|
| Daily secretion volume | ~2–3 L | ~0.1–0.2 L |
| Primary secretory structure | Crypts of Lieberkühn | Colonic crypts (no villi) |
| Goblet cell density | Low (↑ distally) | High throughout |
| Enzyme secretion | Yes (brush border + Brunner's) | Minimal |
| Main secretions | Cl⁻, HCO3⁻, enzymes, mucus | Mucus, HCO3⁻, K+ |
| Paneth cells | Yes (crypts) | No (absence is normal) |
▼ Colonic Bicarbonate & Potassium Secretion
⭐ Unlike the small intestine, the colon is a net secretor of HCO3⁻ and K+, while being a net absorber of Na+ and water.
⚗️ Bicarbonate Secretion (HCO3⁻/Cl⁻ Exchange)
- Mechanism: HCO3⁻/Cl⁻ antiporter on apical membrane → secretes HCO3⁻ into colonic lumen in exchange for Cl⁻ absorption
- Function: Neutralizes acids produced by colonic bacteria (short-chain fatty acids from fermentation); maintains luminal pH
- Stimulated by: Short-chain fatty acids (butyrate, propionate, acetate) from bacterial fermentation; these serve as the primary energy source for colonocytes
- Clinical relevance: In diarrhea, loss of colonic HCO3⁻ → non-anion gap metabolic acidosis (hyperchloremic)
⇧ Potassium Secretion
- Mechanism: K+ secreted into colonic lumen via apical K+ channels (electrogenic); passive secretion down electrochemical gradient
- Regulated by: Aldosterone — increases K+ secretion in colon (same as renal collecting duct); also increases Na+ absorption
- Clinical significance:
- Severe diarrhea → massive K+ loss → hypokalemia
- VIPoma (vasoactive intestinal peptide-secreting tumor) → watery diarrhea, hypokalemia, achlorhydria (WDHA syndrome / "pancreatic cholera")
- Secretory diarrhea: stool K+ concentration very high (unlike osmotic diarrhea)
- Vomiting = loss of HCl → hypochloremic metabolic alkalosis
- Diarrhea = loss of HCO3⁻ from the colon → hyperchloremic metabolic acidosis (non-anion gap) + hypokalemia
- This is a classic board question: identify the acid-base disturbance from a patient with prolonged diarrhea — expect metabolic acidosis with normal anion gap and ↓ K+
▼ GI Hormone Master Table
⭐ The GI tract is the largest endocrine organ in the body. Master this table to answer virtually any hormone-related GI physiology question on Step 1.
📈 Complete GI Hormone Reference
| Hormone | Cell / Location | Stimulus for Release | Target Organs / Effects | Inhibited By |
|---|---|---|---|---|
| Gastrin | G cells (antrum & duodenum) | Peptides/AAs in lumen, stomach distension, vagal ACh/GRP; ↓ gastric pH | ↑ HCl (parietal cells); ↑ gastric motility; ↑ mucosal growth (trophic); stimulates ECL → histamine; ↑ pepsinogen; ↑ intrinsic factor | Somatostatin (D cells when pH <3); secretin; GIP |
| Secretin | S cells (duodenum + jejunum) | Acid (pH <4.5) in duodenum; fat | ↑ Pancreatic HCO3⁻ (centroacinar); ↑ biliary HCO3⁻; ↓ gastric acid; ↓ gastric emptying; stimulates Brunner's glands | ↑ Duodenal pH (neutralization of acid) |
| CCK (Cholecystokinin) | I cells (duodenum + jejunum) | Fat + protein (peptides/AAs) in duodenum | ↑ Pancreatic enzyme secretion (acinar); ↑ gallbladder contraction; ↓ gastric emptying (delays); ↑ Oddi sphincter relaxation; satiety signal via vagus | Somatostatin; trypsin (negative feedback — trypsin degrades CCK-releasing factor) |
| GIP (Gastric Inhibitory Peptide / Glucose-dependent Insulinotropic Peptide) | K cells (duodenum + jejunum) | Fat + AAs + glucose in duodenum | ↑ Insulin secretion (glucose-dependent incretin effect); ↓ gastric acid; minor ↓ gastric motility | ↓ Blood glucose (less insulin needed) |
| GLP-1 | L cells (ileum + colon) | Nutrients in distal gut (CHO, fat) | ↑ Insulin (glucose-dependent); ↓ glucagon; ↓ gastric emptying; satiety (hypothalamus); ↑ beta cell mass | Rapidly degraded by DPP-4 |
| Peptide YY (PYY) | L cells (ileum + colon) | Fat + protein in distal gut | ↓ Appetite; ↓ gastric emptying; ↓ pancreatic secretion; inhibits NPY neurons (ileal brake) | Rises after meals, falls with fasting |
| Motilin | M cells (duodenum + jejunum) | Fasting state (interdigestive period) | Initiates migrating motor complex (MMC) — "intestinal housekeeper"; ↑ gastric emptying; ↑ intestinal peristalsis | Feeding (food suppresses MMC and motilin) |
| Somatostatin | D cells (stomach, duodenum, pancreatic islets) | ↓ Luminal pH, fat, secretin, CCK, sympathetics | Inhibits ALL GI secretion: ↓ gastrin, ↓ secretin, ↓ CCK, ↓ GIP, ↓ insulin, ↓ glucagon; ↓ gastric motility; ↓ pancreatic secretion; ↓ gallbladder contraction | Vagal stimulation (ACh inhibits D cells → disinhibits G cells) |
| VIP (Vasoactive Intestinal Peptide) | ENS neurons throughout GI tract | Neural stimulation (ENS reflex) | ↑ Intestinal secretion (Cl⁻ via cAMP); relaxes smooth muscle; vasodilation; ↑ pancreatic HCO3⁻; inhibits gastric acid; same receptor as secretin (VPAC) | Not a classical circulating hormone — local neurotransmitter |
| Ghrelin | X/A cells (gastric fundus) | Fasting (pre-meal state) | ↑ Appetite (NPY/AgRP); ↑ GH release; ↑ gastric motility/emptying; ↑ fat storage | Eating; GLP-1; somatostatin |
🔬 Clinical Hormone Integration — Tumors & Syndromes
| Condition | Hormone Involved | Key Features |
|---|---|---|
| Zollinger-Ellison Syndrome | ↑ Gastrin (gastrinoma, G cell tumor) | Multiple peptic ulcers (often distal duodenum), diarrhea (acid inactivates lipase → steatorrhea), ↓ response to PPIs, associated with MEN1 |
| VIPoma | ↑ VIP (pancreatic tumor) | WDHA: Watery Diarrhea (secretory), Hypokalemia, Achlorhydria. VIP mimics cholera toxin (↑ cAMP) |
| Carcinoid Syndrome | ↑ Serotonin (5-HT) from EC cells | Flushing, diarrhea, wheezing, tricuspid regurgitation; elevated urine 5-HIAA; occurs after liver metastasis (serotonin not first-pass metabolized) |
| Somatostatinoma | ↑ Somatostatin | "Inhibitory syndrome": diabetes (↓ insulin), gallstones (↓ CCK → ↓ GB motility → stasis), steatorrhea (↓ pancreatic lipase), achlorhydria |
| Type 2 DM Treatment | GLP-1 / GIP (incretin axis) | GLP-1 agonists (semaglutide, liraglutide): ↓ gastric emptying, ↑ satiety, ↓ HbA1c, weight loss. DPP-4 inhibitors (sitagliptin): prevent GLP-1 degradation |
- Secretin = "pro-alkaline" hormone: ↑ pancreatic HCO3⁻, ↓ gastric acid, ↑ Brunner's glands
- CCK = "pro-digestion" hormone: ↑ pancreatic enzymes, ↑ gallbladder, ↓ gastric emptying — source is I-cells (fat + protein)
- GIP vs. GLP-1: Both are incretins (↑ insulin glucose-dependently); GIP from K-cells (duodenum), GLP-1 from L-cells (ileum/colon)
- Motilin = fasting hormone; erythromycin is a motilin agonist (used as prokinetic)
- Somatostatin = the universal GI inhibitor; octreotide (somatostatin analog) used for VIPoma, carcinoid, acromegaly, acute variceal bleeding
🧠 Testing Your Understanding!
Testing Your Understanding — LO 5, Question 1
A patient is found to have a pancreatic tumor secreting somatostatin (somatostatinoma). Predict the clinical triad of symptoms, explaining the mechanism behind each finding from a GI hormone perspective.
Consider: What does somatostatin inhibit in the GI tract and pancreatic islets? Think about ↓ insulin, ↓ CCK, ↓ HCl. How does each lead to the classic triad?
Diabetes: Somatostatin inhibits pancreatic insulin AND glucagon secretion; the net effect is dominant inhibition of insulin → hyperglycemia/diabetes. Gallstones: Somatostatin inhibits CCK release and directly inhibits gallbladder smooth muscle contraction → bile stasis → cholelithiasis (pigment or cholesterol stones from poor GB emptying). Steatorrhea: Somatostatin inhibits CCK → ↓ pancreatic lipase and other enzyme secretion → fat maldigestion → fat malabsorption → steatorrhea. Also achlorhydria (inhibits parietal cells → ↓ HCl), which impairs protein denaturation and pepsin activation. This triad is nicknamed the "inhibitory syndrome" of somatostatinoma.
Testing Your Understanding — LO 5, Question 2
Explain why a patient with a VIPoma presents with severe watery diarrhea AND hypokalemia AND achlorhydria. What is the specific molecular mechanism linking elevated VIP to each component?
Consider: What does VIP do to cAMP in intestinal epithelium? How does massive secretory diarrhea cause hypokalemia? What does VIP do to parietal cells?
Watery diarrhea: VIP binds VPAC1/VPAC2 receptors → activates Gs → ↑↑ cAMP → PKA → opens CFTR channels in intestinal crypts → massive Cl⁻ secretion → Na+ and water follow → voluminous watery (secretory) diarrhea (5–10 L/day). Hypokalemia: Colonic epithelium secretes K+ into the lumen via aldosterone-sensitive K+ channels. When massive diarrhea occurs, K+ is lost in stool at very high concentrations → severe hypokalemia. VIP may also directly stimulate K+ secretion. Achlorhydria: VIP directly inhibits parietal cells (↓ cAMP in parietal cells, acting as an inhibitory signal here) → ↓ HCl secretion → achlorhydria. This WDHA (Watery Diarrhea, Hypokalemia, Achlorhydria) triad is pathognomonic for VIPoma. Treatment: octreotide (somatostatin analog) and surgical resection.
Practice Questions
Lectures 9 & 10 — GI Secretions I & II · HoyaDocs GI Block
LO 1 — Thirst, Hunger & Salivary Secretions (Q1–Q3)
Question 1
A 28-year-old woman with a 2-year history of obesity undergoes Roux-en-Y gastric bypass. Six months postoperatively, she reports markedly reduced hunger despite eating only small meals. Which of the following best explains the hormonal changes responsible for her reduced appetite?
A. Increased ghrelin secretion from the bypassed gastric fundus
B. Decreased secretion of peptide YY and GLP-1 due to reduced caloric intake
C. Decreased ghrelin with increased PYY and GLP-1 due to altered anatomy
D. Increased leptin production from enlarged adipose stores
E. Decreased activity of NPY/AgRP neurons due to leptin hypersensitivity
Roux-en-Y gastric bypass has several hormonal effects: (1) Ghrelin falls — the gastric fundus (primary ghrelin source) is excluded from the alimentary limb → less ghrelin stimulation of NPY/AgRP → less hunger. (2) Food now enters the jejunum rapidly → early, robust stimulation of L-cells in the distal gut → ↑ PYY and GLP-1 → satiety and reduced gastric emptying. Choice A is wrong: ghrelin falls, not rises. B is wrong: PYY/GLP-1 actually increase. D is wrong: 6 months post-op, she has lost weight → less adipose → less leptin. E has no evidence base for leptin hypersensitivity post-bypass.
Question 2
A researcher collects saliva from a subject at rest (low flow rate) and again after maximal gustatory stimulation (high flow rate). Which of the following correctly describes how the electrolyte composition of saliva changes with increasing flow rate?
A. Na+ decreases; K+ increases; osmolarity increases toward isotonicity
B. Na+ increases; K+ decreases slightly; osmolarity remains far below plasma
C. Na+ increases; K+ increases; osmolarity rises to become isotonic with plasma
D. Na+ decreases; K+ remains unchanged; osmolarity remains hypotonic
E. Na+ remains constant; K+ decreases; osmolarity becomes hypertonic
At low flow rates, ductal cells have more time to reabsorb Na+ and secrete K+ → saliva is very hypotonic with very low Na+ and very high K+. At high flow rates, there is less time for ductal modification → the saliva is closer to the primary (acinar) secretion, which is isotonic and plasma-like → Na+ rises (becomes more like plasma), K+ decreases slightly (less time for K+ secretion). However, saliva is ALWAYS hypotonic to plasma — it never reaches isotonicity at any physiological flow rate. Choice C (isotonic) is wrong. Choice A reverses the Na+ direction. Choice E (hypertonic) is never correct for saliva.
Question 3
A 65-year-old woman is prescribed a medication for overactive bladder. Two weeks later, she reports dry mouth and difficulty swallowing. Which of the following is the most likely mechanism by which this drug caused xerostomia?
A. Activation of H2 receptors on acinar cells, reducing cAMP
B. Blockade of M3 muscarinic receptors on salivary acinar cells, reducing IP3/Ca2+ signaling
C. Stimulation of alpha-1 adrenergic receptors, causing vasoconstriction of salivary glands
D. Blockade of nicotinic receptors at the parasympathetic ganglion
E. Inhibition of the submandibular ganglion by CN IX
Overactive bladder is treated with anticholinergic drugs (e.g., oxybutynin, tolterodine, solifenacin) that block M3 muscarinic receptors. Salivary acinar cells are primarily stimulated by parasympathetic ACh acting on M3 receptors → IP3/Ca2+ → chloride channel opening → fluid secretion. Blocking M3 receptors eliminates the dominant salivary stimulus → xerostomia (dry mouth). Choice A: H2 receptors are on parietal cells, not salivary acinar cells. Choice C: while sympathetics cause vasoconstriction and reduce salivary flow, this drug is an anticholinergic, not an alpha-1 agonist. Choice D: nicotinic blockers (ganglionic) would also reduce salivation, but overactive bladder drugs are specifically M3 muscarinic antagonists, not ganglionic blockers. Choice E: CN IX innervates the parotid (via the otic ganglion), not the submandibular.
LO 2 — Gastric Cell Types & HCl Mechanism (Q4–Q6)
Question 4
A 52-year-old woman presents with progressive fatigue, a beefy-red, smooth tongue, and tingling in her hands and feet. Lab work shows macrocytic anemia with hypersegmented neutrophils. Serum gastrin is markedly elevated. Anti-parietal cell antibodies are positive. Which of the following best explains her elevated gastrin?
A. A gastrin-secreting tumor in the pancreas (gastrinoma)
B. Loss of HCl production eliminating the normal acid-mediated inhibition of G cells
C. Excess vagal stimulation of G cells via GRP
D. Decreased somatostatin from D cell hyperplasia
E. Increased CCK from excess fat in the duodenum
This is pernicious anemia from autoimmune atrophic gastritis. Anti-parietal cell antibodies destroy parietal cells → no HCl and no intrinsic factor. Normally, low luminal pH (<3) stimulates D cells to release somatostatin → inhibits G cells → limits gastrin. Without HCl, the luminal pH remains high → no somatostatin release → G cells are tonically active → hypergastrinemia. The elevated gastrin cannot stimulate acid because the parietal cells are destroyed. Neurological symptoms (tingling, subacute combined degeneration) + megaloblastic anemia confirm B12 deficiency from IF loss. Choice A (gastrinoma) would not show anti-parietal cell antibodies. Choices C, D, E do not fit this clinical scenario.
Question 5
A pharmacology student is reviewing the mechanism of a new acid-suppressing drug. The drug is a prodrug that is activated by acid in the secretory canaliculi of parietal cells, after which it irreversibly binds its target by forming a disulfide bond. Which of the following is the rate-limiting step in HCl production that this drug targets?
A. Carbonic anhydrase catalyzing CO2 + H2O → H2CO3
B. H2CO3 dissociation into H+ and HCO3⁻
C. HCO3⁻/Cl⁻ antiporter at the basolateral membrane
D. H+/K+-ATPase (proton pump) at the apical secretory canalicular membrane
E. Cl⁻ channel at the apical membrane secreting Cl⁻ into the lumen
The drug described is a proton pump inhibitor (PPI) — activated by acid in the secretory canaliculi of the parietal cell → forms a sulfenamide → irreversibly binds cysteine residues of H+/K+-ATPase → inactivates the pump. The H+/K+-ATPase is the rate-limiting step in HCl secretion — it directly pumps H+ into the canalicular lumen against a concentration gradient of 3 million-fold. Without this pump, no H+ reaches the gastric lumen regardless of upstream signaling. Choice A (carbonic anhydrase) is not the rate-limiting step and is not targeted by PPIs. Choices B, C, E are not the rate-limiting steps. PPIs are the most effective acid suppressants precisely because they target the final obligatory step.
Question 6
A 35-year-old man undergoes endoscopy for recurrent peptic ulcers. Biopsy of the gastric fundus shows loss of parietal cells and chief cells with replacement by intestinal-type epithelium (intestinal metaplasia). Which of the following digestive functions would be MOST compromised?
A. Digestion of starch by α-amylase in the duodenum
B. Activation of vitamin B12 absorption in the terminal ileum
C. Secretion of CCK from I-cells in response to fat
D. Activation of pancreatic zymogens by enterokinase
E. Synthesis of cholecystokinin from the duodenal mucosa
Loss of parietal cells eliminates both HCl and Intrinsic Factor (IF). IF is exclusively made by parietal cells and is required for B12 absorption at the terminal ileum (cubam receptor). Without IF, dietary B12 cannot be absorbed → B12 deficiency → megaloblastic anemia and neurological complications. While HCl loss also impairs protein digestion (no pepsin activation) and kills bacteria, the question asks what is MOST compromised — B12 absorption has no backup mechanism (unlike, say, protein digestion, which can be partially maintained by pancreatic proteases). Choice A: amylase is from salivary glands and pancreas — not affected. Choices C, D, E: these are duodenal functions unrelated to gastric parietal cells.
LO 3 — Gastric Acid Regulation, H. pylori & Drug Targets (Q7–Q9)
Question 7
During an experiment, a patient smells and sees food but does not eat (sham feeding). Gastric acid output rises to 40% of maximal. This response is completely abolished by atropine. A week later, the experiment is repeated after truncal vagotomy — no acid response is observed with sham feeding. Which phase of gastric secretion and which cranial nerve are responsible?
A. Gastric phase; CN IX (glossopharyngeal)
B. Intestinal phase; CN VII (facial)
C. Cephalic phase; CN X (vagus)
D. Cephalic phase; CN IX (glossopharyngeal)
E. Gastric phase; CN X (vagus)
The cephalic phase is triggered by sight, smell, and anticipation of food — before food enters the stomach. It is mediated 100% by CN X (vagus nerve) via the dorsal motor nucleus. Vagal efferents release ACh onto parietal cells (↑ HCl directly), onto G cells via GRP (↑ gastrin), and inhibit D cells (↓ somatostatin). Atropine blocks ACh at M3 receptors, abolishing the response. Truncal vagotomy cuts the nerve entirely, also abolishing the cephalic phase. CN IX mediates salivary secretion from the parotid, not gastric acid secretion. CN VII mediates submandibular/sublingual salivary glands. The cephalic phase contributes 30–40% of total acid output.
Question 8
A 45-year-old man with confirmed H. pylori infection is started on "triple therapy." The treatment regimen includes a proton pump inhibitor, clarithromycin, and amoxicillin. After completing 14 days of therapy, a urea breath test is performed to confirm eradication. The test involves ingestion of 13C-labeled urea. If H. pylori has been successfully eradicated, what result is expected?
A. Labeled 13CO2 will be detected in exhaled breath, confirming active infection
B. No labeled 13CO2 will be detected in exhaled breath, confirming eradication
C. Elevated serum IgG antibodies against H. pylori, confirming eradication
D. Decreased urea in the blood, indicating active urease activity
E. Increased ammonia in the stool, confirming successful eradication
The urea breath test relies on H. pylori's urease enzyme: if H. pylori is present, its urease cleaves the ingested 13C-labeled urea → 13CO2 + NH3 → 13CO2 is absorbed into blood → exhaled → detected in breath. If H. pylori has been eradicated, there is no urease activity → the 13C-urea is not cleaved → no labeled CO2 in exhaled breath → negative test = eradication confirmed. Choice A describes a POSITIVE test (active infection). Choice C: IgG antibodies persist for months to years after eradication — serology cannot confirm eradication. It's useful for initial diagnosis but not follow-up. Choices D and E are incorrect — they mischaracterize the test mechanism.
Question 9
A pharmaceutical company develops a new drug that acts as a specific agonist at prostaglandin E2 (PGE2) receptors on gastric parietal and mucosal cells. Which of the following best describes the expected GI effects of this drug?
A. Increased HCl secretion and decreased mucosal blood flow
B. Decreased HCl secretion, increased mucus secretion, and maintained mucosal blood flow
C. Increased HCl secretion and increased mucus secretion
D. Decreased HCl secretion and decreased mucus secretion
E. Uterine relaxation and decreased gastric motility only
Endogenous prostaglandins (PGE2, PGI2) exert a cytoprotective effect on the gastric mucosa via multiple mechanisms: (1) Inhibit parietal cell cAMP → ↓ H+/K+-ATPase activity → ↓ HCl secretion; (2) Stimulate mucus and bicarbonate secretion from surface mucous cells; (3) Maintain mucosal blood flow (vasodilation). This is why NSAIDs (COX inhibitors that ↓ prostaglandin synthesis) cause GI ulcers — they remove this protective prostaglandin effect. Misoprostol is a synthetic PGE1 analog that mimics these effects and is used for NSAID ulcer prophylaxis. It can cause uterine contractions (which is why it's used as an abortifacient), but the primary GI effect is cytoprotection, not uterine effects alone (eliminating E).
LO 4 — Pancreatic & Intestinal Secretions (Q10–Q12)
Question 10
A newborn is found to have severe protein malabsorption despite adequate feeding. Endoscopy reveals normal pancreatic structure. Serum trypsinogen levels are markedly elevated, but trypsin activity in the duodenal aspirate is absent. Which of the following is the most likely diagnosis?
A. Cystic fibrosis with exocrine pancreatic insufficiency
B. Zymogen granule release failure due to CCK receptor mutation
C. Enterokinase deficiency causing failure to activate trypsinogen
D. Pancreatic trypsin inhibitor (SPINK1) overexpression blocking trypsin activity
E. Autoimmune destruction of acinar cells with normal ductal function
Enterokinase (enteropeptidase) is a brush border enzyme of the duodenal epithelium that cleaves trypsinogen to trypsin. This is the obligatory first step in the protease activation cascade — without trypsin, no other proteolytic zymogen (chymotrypsinogen, proelastase, procarboxypeptidase) is activated. Trypsinogen is present (secreted normally from acinar cells — elevated serum levels from spillover) but cannot be converted to active trypsin → protein malabsorption. Pancreatic structure is normal (ruling out CF or autoimmune destruction). Treatment: pancreatic enzyme replacement therapy. This is a rare but classic board vignette about the obligate role of enterokinase in the activation cascade. Choice D (SPINK1 overexpression) would suppress pancreatitis but would not prevent enterokinase-mediated activation in the duodenum.
Question 11
A patient with a resected terminal ileum presents with voluminous, greasy stools, weight loss, and fat-soluble vitamin deficiencies. The stool turns red when Sudan red dye is added (steatorrhea confirmed). Which of the following best explains the PRIMARY mechanism of fat malabsorption in this patient?
A. Decreased CCK secretion from I-cells leads to reduced pancreatic lipase output
B. Loss of ileal bile salt reabsorption depletes the bile salt pool, impairing micelle formation
C. Decreased secretin secretion reduces pancreatic HCO3⁻, lowering duodenal pH and inactivating lipase
D. Loss of ileal enteroendocrine cells reduces GLP-1, accelerating gastric emptying and overwhelming absorptive capacity
E. Absence of colipase in the terminal ileum prevents lipase from functioning
The terminal ileum is the exclusive site of enterohepatic bile salt recirculation (via the apical sodium-dependent bile acid transporter, ASBT). 95% of secreted bile salts are reabsorbed here and recycled to the liver. With terminal ileum resection, bile salts are lost in the stool → bile salt pool is depleted → less bile in bile secreted into the duodenum → impaired micelle formation → fat (triglycerides, fat-soluble vitamins A, D, E, K) cannot be solubilized for absorption → steatorrhea. Note: Also B12 deficiency occurs (lost ileal cubam receptors for IF-B12 complex). Choices A and C are secondary effects. Choice D: GLP-1 effects on gastric emptying are minor compared to the bile salt deficit. Choice E: colipase is secreted by the pancreas and activated by trypsin in the duodenum, not in the ileum.
Question 12
A 55-year-old man under great psychological stress develops burning epigastric pain and is found on endoscopy to have duodenal erosions at the proximal duodenum. Which of the following mechanisms best explains why physiological stress specifically predisposes to duodenal mucosal injury?
A. Stress activates the parasympathetic system, increasing acid secretion that overcomes Brunner's gland protection
B. Stress activates the sympathetic system, reducing blood flow to Brunner's glands and inhibiting their mucus secretion
C. Stress increases CRH, which stimulates CCK secretion and increases pancreatic enzyme output
D. Stress increases cortisol, which directly increases parietal cell H+/K+-ATPase expression
E. Stress reduces ghrelin, impairing gastroduodenal mucosal renewal
Brunner's glands (submucosal glands unique to the duodenum) secrete thick alkaline mucus and EGF to protect the duodenal mucosa from acidic chyme. They are stimulated by secretin (acid in duodenum) and vagal ACh, but inhibited by sympathetic stimulation (epinephrine → vasoconstriction → ↓ blood flow to glands → ↓ mucus production). Under stress, ↑ SNS tone → ↓ Brunner's gland function → duodenum is less protected from acid → erosions. Additionally, stress-induced cortisol reduces prostaglandin synthesis → ↓ mucosal protection. Choice A: stress activates SNS, not PSNS. Choice C: CRH does not meaningfully stimulate CCK. Choice D: cortisol has indirect effects (not direct H+/K+-ATPase upregulation). Choice E: ghrelin has no established role in mucosal protection.
LO 5 — Colonic Secretions & GI Hormone Integration (Q13–Q15)
Question 13
A 48-year-old woman undergoes evaluation for recurrent kidney stones (calcium oxalate). She also has episodic flushing, profuse watery diarrhea, and abdominal cramping after meals. Urine 5-HIAA is markedly elevated. CT abdomen shows multiple liver lesions. Which of the following GI hormone-secreting cell type is responsible for her syndrome?
A. G cells secreting gastrin in the gastric antrum
B. S cells secreting secretin in the duodenum
C. Enterochromaffin (EC) cells secreting serotonin
D. I cells secreting CCK in the duodenum
E. K cells secreting GIP in the duodenum
This is carcinoid syndrome from a metastatic carcinoid tumor. EC cells (a subtype of enteroendocrine cells) normally secrete serotonin (5-HT) locally to regulate GI motility. Carcinoid tumors arise from these cells and, once they metastasize to the liver, bypass first-pass hepatic metabolism → serotonin enters systemic circulation → classic carcinoid syndrome: episodic flushing (serotonin + bradykinin + histamine), secretory diarrhea (↑ GI motility), wheezing (bronchoconstriction), and right-sided valvular heart disease (tricuspid regurgitation, pulmonary stenosis). Elevated urine 5-HIAA (5-hydroxyindoleacetic acid, the serotonin metabolite) is pathognomonic. The kidney stone association: serotonin-mediated hyperoxaluria via ↓ oxalate excretion. Treatment: octreotide (somatostatin analog), surgical resection.
Question 14
A pharmaceutical company tests a new drug that inhibits dipeptidyl peptidase-4 (DPP-4), an enzyme that rapidly degrades GLP-1 in the plasma. A type 2 diabetic patient takes this drug before a high-carbohydrate meal. Which of the following effects would be MOST directly enhanced by this drug?
A. Increased glucagon secretion stimulating glycogenolysis
B. Decreased gastric emptying and increased glucose-dependent insulin secretion
C. Increased ghrelin secretion stimulating appetite and GH release
D. Increased secretin secretion from S-cells in response to duodenal acid
E. Increased CCK secretion stimulating gallbladder contraction
DPP-4 inhibitors (gliptins: sitagliptin, saxagliptin, alogliptin) work by preventing the enzymatic degradation of GLP-1 (and GIP) → prolonged GLP-1 activity. Active GLP-1 has multiple effects: (1) Stimulates pancreatic β-cells to secrete insulin in a glucose-dependent manner (the incretin effect — only works when blood glucose is elevated, minimizing hypoglycemia risk); (2) Inhibits glucagon from α-cells; (3) Slows gastric emptying (reduces post-meal glucose spikes); (4) Promotes satiety via hypothalamic receptors. Choice A: GLP-1 inhibits glucagon, so glucagon would decrease. Choice C: GLP-1 has no direct effect on ghrelin. Choices D and E: secretin and CCK are not substrates for DPP-4.
Question 15
A 60-year-old man presents with a 3-week history of profuse, watery diarrhea (8–10 L/day), muscle weakness, and cramps. Labs show: Na+ 138 mEq/L, K+ 2.1 mEq/L, Cl⁻ 110 mEq/L, HCO3⁻ 14 mEq/L. A pancreatic tumor is found on imaging and is found to stain positive for VIP. Which acid-base disturbance and electrolyte abnormality best characterizes this patient?
A. Metabolic alkalosis with hyponatremia
B. Metabolic alkalosis with hypokalemia
C. Metabolic acidosis with hypokalemia (non-anion gap)
D. Respiratory alkalosis with hypokalemia
E. Metabolic acidosis with hypernatremia (non-anion gap)
This is VIPoma (pancreatic cholera / WDHA syndrome). VIP massively activates cAMP in intestinal crypts → CFTR-mediated Cl⁻ secretion → watery diarrhea. The diarrheal fluid contains large amounts of HCO3⁻ (from colonic HCO3⁻/Cl⁻ exchange) and K+ → loss of HCO3⁻ = non-anion gap metabolic acidosis (HCO3⁻ 14, low); loss of K+ = hypokalemia (K+ 2.1). Na+ is normal (isotonic secretory diarrhea). Anion gap = Na⁻ ⁻ (Cl⁻ + HCO3⁻) = 138 ⁻ (110 + 14) = 14 mEq/L (normal = 8⁻12) — borderline, mostly non-AG. Vomiting would cause metabolic alkalosis and hypokalemia (Choice B) — contrast: vomiting = loss of HCl → alkalosis; diarrhea = loss of HCO3⁻ → acidosis. This is a must-know board distinction. Treatment: IV fluid/electrolyte replacement; octreotide to reduce VIP-driven secretion; surgical resection.